Clinical efficacy of Shaomazhijing granules in the treatment of Tourette’s syndrome: a randomized controlled trial

Abstract Objective We designed this study to verify the clinical efficacy and safety of Shaomazhijing granules, a Chinese patent medicine, in the treatment of Tourette's syndrome (TS) with liver-yang hyperactivity, liver wind, and phlegm-fire disturbance. Methods We enrolled a total of 603 chil...

Full description

Saved in:
Bibliographic Details
Main Authors: Yan-Zhen Wang, Jiang Yang, Xin-Min Han
Format: Article
Language:English
Published: BMC 2025-05-01
Series:Hereditas
Subjects:
Online Access:https://doi.org/10.1186/s41065-025-00462-z
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849705312902184960
author Yan-Zhen Wang
Jiang Yang
Xin-Min Han
author_facet Yan-Zhen Wang
Jiang Yang
Xin-Min Han
author_sort Yan-Zhen Wang
collection DOAJ
description Abstract Objective We designed this study to verify the clinical efficacy and safety of Shaomazhijing granules, a Chinese patent medicine, in the treatment of Tourette's syndrome (TS) with liver-yang hyperactivity, liver wind, and phlegm-fire disturbance. Methods We enrolled a total of 603 children and adolescents aged 5–18 years with TS in this randomized, double-blinded, multicenter study. We randomly assigned participants to a Shaomazhijing granules group, a Tiapride group, or a placebo group in a ratio of approximately 3:1:1, respectively. We evaluated the treatment results using the traditional Chinese medicine (TCM) syndrome quantitative classification scale and also compared the incidence of adverse events among the three groups. Results The TCM syndrome of all patients improved over time. At week eight of TCM treatment, the overall syndrome score, primary symptoms (muscle tics), and secondary symptoms (emotional and psychological) of patients in the Shaomazhijing granules and tiapride groups showed significant improvements when compared to that of patients in the placebo group. Compared with the tiapride group, the Shaomazhijing granules group showed better improvement in the secondary symptoms (P < 0.05). While the clinical efficacy for primary symptoms of patients in the Shaomazhijing granules was similar (P = 0.969) with that of patients in tiapride groups. The TCM syndrome clinical control rate and the clinically excellent effectiveness rate of the Shaomazhijing granules group (3.45% and 44.51%) and tiapride group (2.86% and 26.67%) were higher than that of the patients in placebo group (1.04% and 12.50%, P < 0.001). Patients in placebo group (11.2%) and Shaomazhijing granules group (13.8%) had significantly lower overall adverse event rates in comparison with those in tiapride group (26.8%, P = 0.002). Conclusion The clinical efficacy of Shaomazhijing granules is comparable to tiapride in reducing reducing the primary symptoms (muscle tics) of TS. Besides, it showed better efficacy in improving secondary (emotional and psychological) symptoms. Its safety profile is better than tiapride. Based on these results, Shaomazhijing granules can be considered a safe and effective treatment for patients with TS.
format Article
id doaj-art-3d4bec96c93243229e53bbf8cd7fc3d9
institution DOAJ
issn 1601-5223
language English
publishDate 2025-05-01
publisher BMC
record_format Article
series Hereditas
spelling doaj-art-3d4bec96c93243229e53bbf8cd7fc3d92025-08-20T03:16:31ZengBMCHereditas1601-52232025-05-01162111110.1186/s41065-025-00462-zClinical efficacy of Shaomazhijing granules in the treatment of Tourette’s syndrome: a randomized controlled trialYan-Zhen Wang0Jiang Yang1Xin-Min Han2Nanjing University of Chinese MedicineDepartment of Pediatrics, Affiliated Hospital of Nanjing University of Chinese MedicineNanjing University of Chinese MedicineAbstract Objective We designed this study to verify the clinical efficacy and safety of Shaomazhijing granules, a Chinese patent medicine, in the treatment of Tourette's syndrome (TS) with liver-yang hyperactivity, liver wind, and phlegm-fire disturbance. Methods We enrolled a total of 603 children and adolescents aged 5–18 years with TS in this randomized, double-blinded, multicenter study. We randomly assigned participants to a Shaomazhijing granules group, a Tiapride group, or a placebo group in a ratio of approximately 3:1:1, respectively. We evaluated the treatment results using the traditional Chinese medicine (TCM) syndrome quantitative classification scale and also compared the incidence of adverse events among the three groups. Results The TCM syndrome of all patients improved over time. At week eight of TCM treatment, the overall syndrome score, primary symptoms (muscle tics), and secondary symptoms (emotional and psychological) of patients in the Shaomazhijing granules and tiapride groups showed significant improvements when compared to that of patients in the placebo group. Compared with the tiapride group, the Shaomazhijing granules group showed better improvement in the secondary symptoms (P < 0.05). While the clinical efficacy for primary symptoms of patients in the Shaomazhijing granules was similar (P = 0.969) with that of patients in tiapride groups. The TCM syndrome clinical control rate and the clinically excellent effectiveness rate of the Shaomazhijing granules group (3.45% and 44.51%) and tiapride group (2.86% and 26.67%) were higher than that of the patients in placebo group (1.04% and 12.50%, P < 0.001). Patients in placebo group (11.2%) and Shaomazhijing granules group (13.8%) had significantly lower overall adverse event rates in comparison with those in tiapride group (26.8%, P = 0.002). Conclusion The clinical efficacy of Shaomazhijing granules is comparable to tiapride in reducing reducing the primary symptoms (muscle tics) of TS. Besides, it showed better efficacy in improving secondary (emotional and psychological) symptoms. Its safety profile is better than tiapride. Based on these results, Shaomazhijing granules can be considered a safe and effective treatment for patients with TS.https://doi.org/10.1186/s41065-025-00462-zChinese patent medicineShaomazhijing granulesTiaprideTourette’s syndrome
spellingShingle Yan-Zhen Wang
Jiang Yang
Xin-Min Han
Clinical efficacy of Shaomazhijing granules in the treatment of Tourette’s syndrome: a randomized controlled trial
Hereditas
Chinese patent medicine
Shaomazhijing granules
Tiapride
Tourette’s syndrome
title Clinical efficacy of Shaomazhijing granules in the treatment of Tourette’s syndrome: a randomized controlled trial
title_full Clinical efficacy of Shaomazhijing granules in the treatment of Tourette’s syndrome: a randomized controlled trial
title_fullStr Clinical efficacy of Shaomazhijing granules in the treatment of Tourette’s syndrome: a randomized controlled trial
title_full_unstemmed Clinical efficacy of Shaomazhijing granules in the treatment of Tourette’s syndrome: a randomized controlled trial
title_short Clinical efficacy of Shaomazhijing granules in the treatment of Tourette’s syndrome: a randomized controlled trial
title_sort clinical efficacy of shaomazhijing granules in the treatment of tourette s syndrome a randomized controlled trial
topic Chinese patent medicine
Shaomazhijing granules
Tiapride
Tourette’s syndrome
url https://doi.org/10.1186/s41065-025-00462-z
work_keys_str_mv AT yanzhenwang clinicalefficacyofshaomazhijinggranulesinthetreatmentoftourettessyndromearandomizedcontrolledtrial
AT jiangyang clinicalefficacyofshaomazhijinggranulesinthetreatmentoftourettessyndromearandomizedcontrolledtrial
AT xinminhan clinicalefficacyofshaomazhijinggranulesinthetreatmentoftourettessyndromearandomizedcontrolledtrial